Concepts (67)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vulvar Neoplasms | 2 | 2022 | 18 | 0.380 |
Why?
|
| Ovarian Neoplasms | 3 | 2022 | 417 | 0.370 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2022 | 8 | 0.210 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2022 | 16 | 0.210 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 71 | 0.200 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 16 | 0.190 |
Why?
|
| Ribonuclease III | 1 | 2022 | 89 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 121 | 0.180 |
Why?
|
| Parovarian Cyst | 1 | 2020 | 11 | 0.170 |
Why?
|
| Myxoma | 1 | 2020 | 29 | 0.170 |
Why?
|
| Observer Variation | 1 | 2021 | 299 | 0.170 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 411 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2021 | 381 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 279 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 286 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 51 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2020 | 192 | 0.150 |
Why?
|
| Laparoscopy | 2 | 2021 | 491 | 0.150 |
Why?
|
| Endometriosis | 1 | 2021 | 177 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 237 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 201 | 0.140 |
Why?
|
| Fertility Preservation | 1 | 2017 | 53 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 662 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1008 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2022 | 1177 | 0.090 |
Why?
|
| Female | 8 | 2022 | 66186 | 0.060 |
Why?
|
| Perilipin-2 | 1 | 2022 | 10 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1474 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 1134 | 0.050 |
Why?
|
| Accreditation | 1 | 2022 | 87 | 0.050 |
Why?
|
| Humans | 9 | 2022 | 124005 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 3580 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 4768 | 0.040 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2020 | 58 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2021 | 192 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 611 | 0.040 |
Why?
|
| Child | 4 | 2020 | 24327 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2018 | 39 | 0.040 |
Why?
|
| Granulosa Cell Tumor | 1 | 2018 | 40 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 125 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 130 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2021 | 16239 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 515 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2018 | 231 | 0.030 |
Why?
|
| Mutation | 2 | 2022 | 5794 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1421 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Laparotomy | 1 | 2017 | 135 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 671 | 0.030 |
Why?
|
| Ovary | 1 | 2018 | 379 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 772 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 991 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 723 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1223 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1233 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 3134 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1266 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 5126 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 4605 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 19222 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6461 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2018 | 2586 | 0.020 |
Why?
|
| United States | 1 | 2022 | 10853 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 12262 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 19516 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 26569 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 29292 | 0.010 |
Why?
|